Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

425P - Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)

Date

21 Oct 2023

Session

Poster session 03

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Blanca Tavara

Citation

Annals of Oncology (2023) 34 (suppl_2): S334-S390. 10.1016/S0923-7534(23)01260-7

Authors

B.I. Tavara, M.L. Garrido, L. Lopez, M. Lopez Flores, C. Castañón, S. Abella Alvarez, S. Medina Valdivieso, A. Rodriguez Sanchez, A. García Palomo-Pérez, A. López

Author affiliations

  • Medical Oncology Department, Complejo Asistencial Universitario de León - Hospital de León, 24071 - León/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 425P

Background

Palbociclib, ribociclib and abemaciclib play an important role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) BC based on their impressive efficacy; however, there seem to be some differences in toxicity profiles which can adversely affect their QoL. This study aims to evaluate health-related QoL (HRQoL) in advanced BC patients treated with CDK4/6i with the help of digital apps.

Methods

HRQoL was assessed in women with HR+/HER2- metastatic BC treated with CDK4/6i plus endocrine therapy using the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire via online platform in Spanish patients with a cut-off date of August 2022.

Results

A total of 264 patients were analyzed. 85% had between 40-69 years. 30% were employed. The most used CDK4/6i was palbociclib (46.2%), followed of ribociclib (39.8%) and abemaciclib (14%). 33% had a dose reduction. 69.7% of patients had received chemotherapy previously; of these, 91.8% consider that their QoL is better with CDK4/6i. Of all patients who are undergoing with CDK4/6i, 87.5% feel content with the treatment. Overall scores from the FACT-B questionnaire were comparable between all CDK4/6i (Table). Notably, 45.9% and 37.8% of patients in the abemaciclib group reported diarrhea and nausea, respectively. Better scores were registered in the palbociclib arm for fatigue, pain, insomnia and better sexual enjoyment. Table: 425P

FACT-B* Palbociclib Ribociclib Abemaciclib p value
N (%) 122 (46.3%) 105 (39.7%) 37 (14%)
Age (%)≤ 39 years40-69 years≥ 70 years 11 (9.02%)105 (86.07%)6 (4.92%) 14 (13.33%)89 (84.76%)2 (1.91%) 7 (18.98%)30 (81.08%)0 0,232
Physical well-being, median (range) 22 (4-28) 21 (1-28) 20 (9-27) 0,431
Social/family well-being, median (range) 17 (0-27) 18 (0-24) 18 (5-26) 0,48
Emotional well-being, median (range) 14 (3-24) 10 (0-18) 13 (6-20) 0,005
Functional well-being, median (range) 13.5 (0-26) 14 (1-27) 13 (1-23) 0,855
Breast cancer subscale, median (range) 24 (7-39) 23 (4-35) 20 (13-32) 0,027
Total score, median (range) 90 (24-135) 86 (29-127) 83 (53-104) 0,049

*Higher scores indicate a better QoL.

Conclusions

The CDK4/6i play an eminent role in the therapy of advanced BC; nevertheless, the impact of treatment in QoL should be considered in addition to efficacy and safety, especially in the non-curative setting. Our HR-QoL results seems to confirm those obtained in clinical trials. To our knowledge this is the first study about HR-QoL in HR+/HER2- BC patients treated with CDK4/6i in Spanish real-world setting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.